Calcium phosphate cement;
Bone repair;
Chemotherapy;
Drug delivery;
DIMETHYL-SULFOXIDE;
ACRYLIC CEMENT;
BREAST-CANCER;
METHOTREXATE;
METASTASIS;
HYDROXYAPATITE;
THERAPY;
BIOMATERIALS;
CARCINOMA;
SKELETON;
D O I:
10.1016/j.biomaterials.2011.04.010
中图分类号:
R318 [生物医学工程];
学科分类号:
100103 [病原生物学];
摘要:
Bone metastases are usually treated by surgical removal, fixation and chemotherapeutic treatment. Bone cement is used to fill the resection voids. The aim of this study was to develop a local drug delivery system using a calcium phosphate cement (CPC) as carrier for chemotherapeutic agents. CPC consisted of alpha-tricalcium phosphate, calcium phosphate dibasic and precipitated hydroxyapatite powders and a 2% Na(2)HPO(4) hardening solution. Scanning electron microscopy (SEM) was used to observe CPC morphology. X-ray diffraction (XRD) was used to follow CPC transformation. The loading/release capacity of the CPC was studied by a bovine serum albumin-loading model. Release/retention was measured by high performance liquid chromatography and X-ray photoelectron spectrometry. For chemotherapeutic loading, paclitaxel (PX) was loaded onto the CPC discs by absorption. Viability of osteosarcoma U2OS and metastatic breast cancer MDA-MB-231 cells was measured by an AlamarBlue assay. Results of SEM and XRD showed changes in CPC due to its transformation. The loading model indicated a high retention behavior by the CPC composition. Cell viability tests indicated a PX minimal lethal dose of 90 mu g/ml. PX released from CPC remained active to influence cell viability. In conclusion, this study demonstrated that CPC is a feasible delivery vector for chemotherapeutic agents. (C) 2011 Elsevier Ltd. All rights reserved.